AI-generated summary
The authors retrospectively studied 10 adults with bilateral glottal papillomatosis who had prior laser treatment and recurrence, adding bevacizumab injections to 532-nm pulsed KTP laser treatments. They report that all patients had a greater than 90% reduction in recurrence, four had resolution, and all showed improved vocal function. The authors describe this as preliminary evidence from a pilot group.
- Participants
- 10
- Who or what was studied
- Adult patients with bilateral glottal papillomatosis and prior angiolytic laser treatment with established recurrence patterns
- Wavelengths
- 532 nm
- Limits stated in the abstract
- This is a retrospective pilot study of only 10 patients, described by the authors as preliminary evidence.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Laser. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.